Deloitte Life Sciences Catalyst - Next Generation Therapies

Cell and gene therapies have the potential to revolutionise medical care, by eliminating the underlying cause of genetic and acquired diseases. It is one of the most exciting biopharma segments with relatively recent ground-breaking scientific advances driving rapid growth, and with staggering predictions for the future success of the industry. Yet, the wider economics of delivering next gen therapies - including payment models and affordability – are highly debated and not well understood.

Dates Wednesday, October 20, 2021 - Download as vCalendar
Event Times: 13:30
Venue A zoom webinar.
Contact Name Claire Campbell
Website Event website

Event details:

The guest panel will include:

  • Dr Jacqueline Barry, Chief Clinical Officer, Cell & Gene Catapult
  • Colin Terry, Partner and UK Consulting Life Sciences Lead, Deloitte
  • Liz Hampson, Director, Life Sciences Strategy Consulting, Deloitte
  • Karen Taylor, Director, Centre for Health Solutions, Deloitte

In this hour long webinar, the panel will discuss:

  • Industry trends and future expectations
  • How to navigate market access and reimbursement processes and the role of innovative contracting
  • Considerations for the delivery of cell and gene therapies from a healthcare system perspective
  • Overcoming the nuanced challenges in next gen R&D and realising a return on investment
  • A company case study
  • Live questions from the audience

The Deloitte Cambridge office comprises 8 Partners and over 250 staff who deliver a full range of professional services to the East Anglian region. As well as focussing on the life sciences and technology sectors for which the region has become so renowned, the office has long standing specialisms in other sectors including the professions, consumer business, food and agribusiness.